RU2019139432A - Фармакокинетическая оптимизация бифункциональных хелатов и их применение - Google Patents
Фармакокинетическая оптимизация бифункциональных хелатов и их применение Download PDFInfo
- Publication number
- RU2019139432A RU2019139432A RU2019139432A RU2019139432A RU2019139432A RU 2019139432 A RU2019139432 A RU 2019139432A RU 2019139432 A RU2019139432 A RU 2019139432A RU 2019139432 A RU2019139432 A RU 2019139432A RU 2019139432 A RU2019139432 A RU 2019139432A
- Authority
- RU
- Russia
- Prior art keywords
- acid
- paragraphs
- compound
- cancer
- optionally substituted
- Prior art date
Links
- 230000001588 bifunctional effect Effects 0.000 title 1
- 238000005457 optimization Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 24
- 238000000034 method Methods 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 6
- 230000002285 radioactive effect Effects 0.000 claims 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 238000004132 cross linking Methods 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 229910052751 metal Inorganic materials 0.000 claims 4
- 239000002184 metal Substances 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- BYBCIVKIWIFVFD-UHFFFAOYSA-N 2-[4,10-bis(carboxymethyl)-7-(2,6-dioxooxan-3-yl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound C1CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CCN1C1C(=O)OC(=O)CC1 BYBCIVKIWIFVFD-UHFFFAOYSA-N 0.000 claims 2
- FQIHLPGWBOBPSG-UHFFFAOYSA-N 2-[4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetamide Chemical compound NC(=O)CN1CCN(CC(N)=O)CCN(CC(N)=O)CCN(CC(N)=O)CC1 FQIHLPGWBOBPSG-UHFFFAOYSA-N 0.000 claims 2
- DFPHZEYJGWLQJE-UHFFFAOYSA-N 2-[4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound NC(=O)CN1CCN(CC(N)=O)CCN(CC(O)=O)CCN(CC(N)=O)CC1 DFPHZEYJGWLQJE-UHFFFAOYSA-N 0.000 claims 2
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims 2
- SYFGLWDDLZQFNI-UHFFFAOYSA-N 2-[4-(carboxymethyl)-1,4,8,11-tetrazabicyclo[6.6.2]hexadecan-11-yl]acetic acid Chemical compound C1CN(CC(O)=O)CCCN2CCN(CC(=O)O)CCCN1CC2 SYFGLWDDLZQFNI-UHFFFAOYSA-N 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 2
- JVHROZDXPAUZFK-UHFFFAOYSA-N TETA Chemical compound OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CCCN(CC(O)=O)CC1 JVHROZDXPAUZFK-UHFFFAOYSA-N 0.000 claims 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical group OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 2
- RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 claims 2
- 150000001345 alkine derivatives Chemical class 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 230000004957 immunoregulator effect Effects 0.000 claims 2
- -1 methylene phosphonic acid Chemical compound 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims 2
- MINYUAZSXIWCRA-UHFFFAOYSA-N 1,4,7,10,13-pentazacyclohexadec-12-ene Chemical compound N1=CCNCCNCCNCCNCCC1 MINYUAZSXIWCRA-UHFFFAOYSA-N 0.000 claims 1
- PBYIIRLNRCVTMQ-UHFFFAOYSA-N 2,3,5,6-tetrafluorophenol Chemical compound OC1=C(F)C(F)=CC(F)=C1F PBYIIRLNRCVTMQ-UHFFFAOYSA-N 0.000 claims 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims 1
- OLOMBAYFBVCLCE-UHFFFAOYSA-N 2-[1,2,5,11,14-pentakis(carboxymethyl)-1,2,5,8,11,14-hexazacyclohexadec-8-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)N(CC(O)=O)CCN(CC(O)=O)CC1 OLOMBAYFBVCLCE-UHFFFAOYSA-N 0.000 claims 1
- RAEOEMDZDMCHJA-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-[2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]ethyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CCN(CC(O)=O)CC(O)=O)CC(O)=O RAEOEMDZDMCHJA-UHFFFAOYSA-N 0.000 claims 1
- GTACSIONMHMRPD-UHFFFAOYSA-N 2-[4-[2-(benzenesulfonamido)ethylsulfanyl]-2,6-difluorophenoxy]acetamide Chemical compound C1=C(F)C(OCC(=O)N)=C(F)C=C1SCCNS(=O)(=O)C1=CC=CC=C1 GTACSIONMHMRPD-UHFFFAOYSA-N 0.000 claims 1
- RZESKRXOCXWCFX-UHFFFAOYSA-N 2-[bis[2-[carboxymethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetic acid Chemical compound CNC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NC RZESKRXOCXWCFX-UHFFFAOYSA-N 0.000 claims 1
- JFFBRAJWMUULTF-UHFFFAOYSA-N 3-(1,2,3,4-tetrazacyclododec-1-yl)propan-1-ol Chemical compound OCCCN1CCCCCCCCNNN1 JFFBRAJWMUULTF-UHFFFAOYSA-N 0.000 claims 1
- AQWXHYUWFUXFFH-UHFFFAOYSA-N 3-[4,7,10-tris(2-carboxyethyl)-1,4,7,10-tetrazacyclododec-1-yl]propanoic acid Chemical compound OC(=O)CCN1CCN(CCC(O)=O)CCN(CCC(O)=O)CCN(CCC(O)=O)CC1 AQWXHYUWFUXFFH-UHFFFAOYSA-N 0.000 claims 1
- SOUJYUTZZAWCOV-UHFFFAOYSA-N 3-[4,8,11-tris(2-carboxyethyl)-1,4,8,11-tetrazacyclotetradec-1-yl]propanoic acid Chemical compound OC(=O)CCN1CCCN(CCC(O)=O)CCN(CCC(O)=O)CCCN(CCC(O)=O)CC1 SOUJYUTZZAWCOV-UHFFFAOYSA-N 0.000 claims 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 101710130081 Aspergillopepsin-1 Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108091035707 Consensus sequence Proteins 0.000 claims 1
- 102100031007 Cytosolic non-specific dipeptidase Human genes 0.000 claims 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 102000002090 Fibronectin type III Human genes 0.000 claims 1
- 108050009401 Fibronectin type III Proteins 0.000 claims 1
- IQUHNCOJRJBMSU-UHFFFAOYSA-N H3HP-DO3A Chemical compound CC(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 IQUHNCOJRJBMSU-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims 1
- TTZMPOZCBFTTPR-UHFFFAOYSA-N O=P1OCO1 Chemical compound O=P1OCO1 TTZMPOZCBFTTPR-UHFFFAOYSA-N 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 229910052772 Samarium Inorganic materials 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 claims 1
- 229910052768 actinide Inorganic materials 0.000 claims 1
- 150000001255 actinides Chemical class 0.000 claims 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 229910052797 bismuth Inorganic materials 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229910052804 chromium Inorganic materials 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 229960000958 deferoxamine Drugs 0.000 claims 1
- BJAJDJDODCWPNS-UHFFFAOYSA-N dotp Chemical compound O=C1N2CCOC2=NC2=C1SC=C2 BJAJDJDODCWPNS-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960001484 edetic acid Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 claims 1
- 229910052733 gallium Inorganic materials 0.000 claims 1
- 125000005179 haloacetyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 229910052738 indium Inorganic materials 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 150000002540 isothiocyanates Chemical class 0.000 claims 1
- 229910052747 lanthanoid Inorganic materials 0.000 claims 1
- 150000002602 lanthanoids Chemical class 0.000 claims 1
- 229910052745 lead Inorganic materials 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229910052748 manganese Inorganic materials 0.000 claims 1
- QQYYPOJIFYBSDU-UHFFFAOYSA-N methyl 6-(2-aminopropylamino)pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(NCC(C)N)=N1 QQYYPOJIFYBSDU-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- SJGALSBBFTYSBA-UHFFFAOYSA-N oxaziridine Chemical compound C1NO1 SJGALSBBFTYSBA-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960003330 pentetic acid Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 150000004032 porphyrins Chemical class 0.000 claims 1
- 229910052702 rhenium Inorganic materials 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011163 secondary particle Substances 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 229910052727 yttrium Inorganic materials 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502260P | 2017-05-05 | 2017-05-05 | |
| US62/502,260 | 2017-05-05 | ||
| PCT/US2018/031228 WO2018204869A1 (en) | 2017-05-05 | 2018-05-04 | Pharmacokinetic enhancements of bifunctional chelates and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019139432A true RU2019139432A (ru) | 2021-06-07 |
| RU2019139432A3 RU2019139432A3 (enExample) | 2021-06-16 |
Family
ID=64016761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019139432A RU2019139432A (ru) | 2017-05-05 | 2018-05-04 | Фармакокинетическая оптимизация бифункциональных хелатов и их применение |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11191854B2 (enExample) |
| EP (1) | EP3619191A4 (enExample) |
| JP (2) | JP7693317B2 (enExample) |
| KR (1) | KR102612882B1 (enExample) |
| CN (2) | CN111263747B (enExample) |
| AU (3) | AU2018261888B2 (enExample) |
| BR (1) | BR112019023246B1 (enExample) |
| CA (1) | CA3062553C (enExample) |
| CL (1) | CL2019003168A1 (enExample) |
| EA (1) | EA201992595A1 (enExample) |
| IL (1) | IL270453B2 (enExample) |
| MA (1) | MA48861A (enExample) |
| RU (1) | RU2019139432A (enExample) |
| WO (1) | WO2018204869A1 (enExample) |
| ZA (1) | ZA201908071B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10758636B2 (en) * | 2013-11-12 | 2020-09-01 | Centre For Probe Development And Commercialization | Residualizing linkers and uses thereof |
| JP7191938B2 (ja) * | 2017-05-05 | 2022-12-19 | センター・フォー・プローブ・デベロップメント・アンド・コマーシャライゼイション | Ｉｇｆ－１ｒモノクローナル抗体及びその使用 |
| RU2019139432A (ru) | 2017-05-05 | 2021-06-07 | Сентр фор Проуб Девелопмент энд Коммерсиализэйшн | Фармакокинетическая оптимизация бифункциональных хелатов и их применение |
| US20210236664A1 (en) * | 2018-04-25 | 2021-08-05 | The Johns Hopkins University | Alpha particle formulations for treatment of solid tumors |
| AU2019287595B2 (en) * | 2018-04-27 | 2024-10-31 | University Of Iowa Research Foundation | Compositions for chelating metals at low temperatures |
| MA54401A (fr) * | 2018-12-03 | 2021-10-13 | Fusion Pharmaceuticals Inc | Polythérapie associant des radioimmunoconjugués et des inhibiteurs de réparation des dommages à l'adn |
| AU2019435951B2 (en) * | 2019-03-20 | 2025-08-14 | Provincial Health Services Authority | Chelators and methods of making and using same |
| EP4087621A4 (en) * | 2020-01-10 | 2024-01-17 | Fusion Pharmaceuticals Inc. | MACROCYCLIC CHELATES AND USES THEREOF |
| BR112022013681A2 (pt) * | 2020-01-10 | 2022-11-16 | Fusion Pharmaceuticals Inc | Imunoterapia sustentada |
| WO2021195131A1 (en) * | 2020-03-23 | 2021-09-30 | Fusion Pharmaceuticals Inc. | Fgfr3-targeted radioimmunoconjugates and uses thereof |
| KR102362962B1 (ko) * | 2020-06-12 | 2022-02-16 | (주)미래바이오팜 | 신규한 화합물 및 이를 함유하는 신경 손상, 신경 질환, 또는 발달 장애에 대한 신경세포의 증식 촉진, 분화, 및/또는 재생을 통한 치료 또는 예방용 약제학적 조성물 |
| WO2022025184A1 (ja) * | 2020-07-29 | 2022-02-03 | 中外製薬株式会社 | 非放射性物質で標識した薬剤の薬物動態を測定する方法 |
| WO2022198319A1 (en) * | 2021-03-23 | 2022-09-29 | Fusion Pharmaceuticals Inc. | Use of a cold fgfr3-targeting molecule and a fgfr3 targeting radioimmunoconjugate for treating cancer |
| WO2022266499A1 (en) * | 2021-06-17 | 2022-12-22 | Mayo Foundation For Medical Education And Research | Methods and materials for combining biologics with multiple chelators |
| WO2023164777A1 (en) * | 2022-03-04 | 2023-09-07 | Fusion Pharmaceuticals Inc. | Gucy2c-targeted radiopharmaceuticals and use thereof |
| WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
| EP4637843A2 (en) * | 2022-12-21 | 2025-10-29 | Mayo Foundation for Medical Education and Research | Methods and materials for combining biologics with multiple chelators |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5175343A (en) | 1985-01-14 | 1992-12-29 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
| DE3713842A1 (de) * | 1987-04-22 | 1988-11-17 | Schering Ag | Substituierte cyclische komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel |
| US4889931A (en) | 1988-09-27 | 1989-12-26 | Salutar, Inc. | Manganese (II) chelate manufacture |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE133165T1 (de) | 1989-02-10 | 1996-02-15 | Celltech Therapeutics Ltd | Aza-macrozyklen und verfahren zu deren herstellung |
| US5053503A (en) | 1989-02-17 | 1991-10-01 | Centocor | Chelating agents |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US6274713B1 (en) | 1989-04-07 | 2001-08-14 | Salutar, Inc. | Polychelants |
| US7385041B2 (en) | 1990-04-25 | 2008-06-10 | Bracco International B.V. | Dual functioning excipient for metal chelate contrast agents |
| CA2044737A1 (en) | 1990-06-18 | 1991-12-19 | Jaime Simon | Use of macrocyclic aminophosphonic acid complexes as imaging agents |
| US5386011A (en) | 1990-12-27 | 1995-01-31 | Abbott Laboratories | Hexapeptide anaphylatoxin-receptor ligands |
| GB9112536D0 (en) * | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| AU2238292A (en) | 1991-06-14 | 1993-01-12 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| CA2134239C (en) | 1992-06-09 | 2004-11-23 | Donald B. Axworthy | Pretargeting methods and compounds |
| US5358704A (en) | 1993-09-30 | 1994-10-25 | Bristol-Myers Squibb | Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents |
| GB9504922D0 (en) | 1995-03-10 | 1995-04-26 | Nycomed As | Process |
| SI0970126T1 (en) | 1997-04-14 | 2001-08-31 | Micromet Ag | Novel method for the production of antihuman antigen receptors and uses thereof |
| IT1291624B1 (it) | 1997-04-18 | 1999-01-11 | Bracco Spa | Chelati complessi di metalli paramagnetici a bassa tossicita' |
| IT1304501B1 (it) | 1998-12-23 | 2001-03-19 | Bracco Spa | Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza |
| CA2371728C (en) | 1999-06-11 | 2009-06-02 | Neorx Corporation | High dose radionuclide complexes for bone marrow suppression |
| DE10002939C1 (de) | 2000-01-13 | 2001-09-20 | Schering Ag | Paramagnetische DOTA-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung für die Herstellung von pharmazeutischen Mitteln |
| US20020052354A1 (en) | 2000-01-27 | 2002-05-02 | Schering Ag | Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction |
| US6264966B1 (en) | 2000-02-22 | 2001-07-24 | Concat, Ltd. | Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury |
| JP2004509152A (ja) | 2000-05-12 | 2004-03-25 | ユニバーシティ ホスピタル | 放射性金属標識分子のプロキレート剤 |
| JP2004536034A (ja) | 2001-01-08 | 2004-12-02 | ネオルクス コーポレイション | 治療的および診断的化合物、組成物および方法 |
| DE10135355C1 (de) | 2001-07-20 | 2003-04-17 | Schering Ag | Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie |
| DE10135356C1 (de) | 2001-07-20 | 2003-04-17 | Schering Ag | Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen |
| TWI240632B (en) | 2001-07-30 | 2005-10-01 | Epix Medical Inc | Purified peptides for peptide-based multimeric targeted contrast agents |
| EP1542709A2 (en) | 2002-08-06 | 2005-06-22 | EPIX Pharmaceuticals, Inc. | Peptide aggregates |
| DE10250870A1 (de) | 2002-10-31 | 2004-05-13 | Switch Biotech Ag | Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung |
| JP2006517558A (ja) | 2003-02-13 | 2006-07-27 | ブラッコ イメージング エッセ ピ ア | コントラスト増強ｘ線位相画像診断 |
| EP1603598B1 (en) * | 2003-03-19 | 2008-10-08 | Universitätsspital Basel | Radiolabeled conjugates based on substance p and the uses thereof |
| CA2526760A1 (en) | 2003-05-23 | 2005-01-06 | Epix Pharmaceuticals, Inc. | Optically pure and enriched isomers of chelating ligands and contrast agents |
| JP4262545B2 (ja) | 2003-07-09 | 2009-05-13 | 三菱電機株式会社 | カスコード接続回路及びその集積回路 |
| JP2007505315A (ja) | 2003-09-12 | 2007-03-08 | インヴィトロジェン コーポレーション | 多重結合および活性アッセイ |
| AU2004303425C1 (en) | 2003-12-19 | 2010-02-18 | Schering Corporation | Pharmaceutical compositions |
| WO2005079803A1 (en) | 2004-02-13 | 2005-09-01 | Pfizer Products, Inc. | Compounds for treatment of cardiovascular diseases |
| WO2006015318A2 (en) | 2004-07-30 | 2006-02-09 | Biogen Idec Inc. | Antibody conjugated to a drug moiety via a poptidic linker |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| US20060222595A1 (en) | 2005-03-31 | 2006-10-05 | Priyabrata Mukherjee | Nanoparticles for therapeutic and diagnostic applications |
| US7618957B2 (en) | 2005-07-15 | 2009-11-17 | Bayer Schering Pharma Aktiengesellschaft | Perfluoroalkyl-containing complexes, process for their production as well as their use |
| EP1904462A2 (de) | 2005-07-15 | 2008-04-02 | Bayer Schering Pharma Aktiengesellschaft | Perfluoralkylhaltige komplexe, verfahren zu deren herstellung, sowie deren verwendung |
| US20100226884A1 (en) * | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
| US8034898B2 (en) | 2005-12-29 | 2011-10-11 | Collagen Medical, LLC | Methods of collagen imaging |
| EP2065057A3 (en) | 2006-03-15 | 2009-08-12 | Mallinckrodt Inc. | Chelating conjugates having a substituted aromatic moiety and derivatives thereof |
| US7777029B2 (en) | 2006-05-02 | 2010-08-17 | San Diego State University (Sdsu) Foundation | Bifunctional chelators for sequestering lanthanides |
| US20080213811A1 (en) | 2006-08-11 | 2008-09-04 | Invitrogen Corporation | Sensor proteins and assay methods |
| US8691761B2 (en) * | 2006-10-16 | 2014-04-08 | Jean E. F. Rivier | Somatostatin receptor 2 antagonists |
| GB0624587D0 (en) | 2006-12-08 | 2007-01-17 | Univ Muenchen Tech | Chelating agent |
| US20100111858A1 (en) * | 2007-01-19 | 2010-05-06 | Howard Carol P | Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands |
| WO2008134289A2 (en) | 2007-04-26 | 2008-11-06 | Mallinckrodt Inc. | High relaxivity coordinatively unsaturated lanthanide complexes |
| ES2676598T3 (es) | 2007-08-27 | 2018-07-23 | Liebel-Flarsheim Company Llc | Eliminación de sílice a partir de compuestos hidrosolubles mediante nanofiltración y cromatografía en fase inversa |
| CA2697612A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Anti-igf-1r antibodies and uses thereof |
| US20090208421A1 (en) | 2008-02-19 | 2009-08-20 | Dominique Meyer | Process for preparing a pharmaceutical formulation of contrast agents |
| DE102008045937B4 (de) | 2008-04-11 | 2017-01-26 | Johannes-Gutenberg-Universität Mainz | Radiopharmakon aus einem Metallion und einem Markierungsvorläufer und Verwendung des Radiopharmakons |
| US8546531B2 (en) | 2008-07-16 | 2013-10-01 | The General Hospital Corporation | Methods and reagents for preparing multifunctional probes |
| EP2147684A1 (en) | 2008-07-22 | 2010-01-27 | Bracco Imaging S.p.A | Diagnostic Agents Selective Against Metalloproteases |
| CN102271713B (zh) | 2008-11-06 | 2013-07-31 | 路易莎·布拉奇 | 神经降压肽衍生的分枝肽及其用途 |
| WO2010088527A2 (en) | 2009-01-30 | 2010-08-05 | Mayo Foundation For Medical Education And Research | Peptides and nanoparticles for therapeutic and diagnostic applications |
| MX2011009716A (es) | 2009-03-19 | 2011-10-17 | Wyeth Llc | Metodos para la preparacion de acido [2-(8,9-dioxo)-2,6-diazabicic lo[5.2.0]non-1(7)-en-2-il)etil]fosfonico y precursores de este. |
| WO2011005609A2 (en) | 2009-07-08 | 2011-01-13 | Mayo Foundation For Medical Education And Research | Imaging gastrointestinal volumes and motility |
| EP2515914A4 (en) | 2009-12-23 | 2013-09-11 | Scripps Research Inst | BIOCONJUGATION OF TYROSINE BY EYE REACTIONS IN AQUEOUS MEDIA |
| EP3075390A1 (en) | 2010-01-19 | 2016-10-05 | Immunomedics Inc. | Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r) |
| EP2397466B1 (en) | 2010-06-15 | 2012-11-28 | Centre National De La Recherche Scientifique CNRS | X-ray and gamma-photon activatable organic compounds, their preparation and their uses |
| US9573978B2 (en) | 2010-08-12 | 2017-02-21 | S&T Global, Inc. | Cyclosporin derivatives for the treatment and prevention of a viral infection |
| US12097269B2 (en) | 2010-10-27 | 2024-09-24 | Vikas Kundra | Dual mode gadolinium nanoparticle contrast agents |
| FR2968999B1 (fr) | 2010-12-20 | 2013-01-04 | Guerbet Sa | Nanoemulsion de chelate pour irm |
| US20140088019A1 (en) | 2011-02-11 | 2014-03-27 | Zyngenia, Inc. | Monovalent and Multivalent Multispecific Complexes and Uses Thereof |
| WO2012122420A2 (en) | 2011-03-09 | 2012-09-13 | Pharmacofore, Inc. | Opioid prodrugs with heterocyclic linkers |
| PL2721045T3 (pl) | 2011-06-20 | 2017-11-30 | Radiomedix Inc. | Kompozycie, metody syntezy i zastosowanie węglowodanowych środków ukierunkowanych |
| FR2976825B1 (fr) | 2011-06-22 | 2014-02-21 | Total Sa | Nanotraceurs pour le marquage d'eaux d'injection de champs petroliers |
| EP2604281B1 (en) | 2011-12-14 | 2014-07-30 | Centre National de la Recherche Scientifique (CNRS) | Clicked somatostatin conjugated analogs for biological applications |
| KR20130083592A (ko) | 2012-01-13 | 2013-07-23 | 현대약품 주식회사 | 치환된 피페리딘 유도체 및 이의 제조방법 |
| EP2852685A1 (en) | 2012-03-30 | 2015-04-01 | Merck Sharp & Dohme Corp. | Igf1 biomarker for igf1r inhibitor therapy |
| KR20150030709A (ko) | 2012-06-14 | 2015-03-20 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 췌장 내분비 세포로의 분화 |
| CN102743770B (zh) | 2012-06-18 | 2017-07-21 | 申宝忠 | 一种靶向性分子成像探针及活体分子成像方法 |
| EP2892570B1 (en) | 2012-09-07 | 2019-02-27 | Bracco Imaging S.p.A | Paramagnetic solid lipid nanoparticles (pslns) containing metal amphiphilic complexes for mri |
| US9931412B2 (en) | 2013-02-08 | 2018-04-03 | The Regents Of The University Of Michigan | Targeted theranostics |
| CA2911259A1 (en) | 2013-05-06 | 2014-11-13 | Merck Patent Gmbh | Macrocycles as kinase inhibitors |
| WO2015023979A1 (en) | 2013-08-16 | 2015-02-19 | Equip, Llc | Discrete peg constructs |
| US10471163B2 (en) | 2013-09-13 | 2019-11-12 | The General Hospital Corporation | Activatable fibrin-binding probes |
| AU2014336638C1 (en) | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| US10758636B2 (en) * | 2013-11-12 | 2020-09-01 | Centre For Probe Development And Commercialization | Residualizing linkers and uses thereof |
| WO2015085005A1 (en) | 2013-12-03 | 2015-06-11 | The General Hospital Corporation | Molecular imaging probes |
| FR3015547B1 (fr) | 2013-12-20 | 2016-01-01 | Total Sa | Methode pour ajuster le taux d'inhibiteurs dans un puits de petrole ou de gaz |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| CN106459205B (zh) | 2014-04-11 | 2021-04-09 | 免疫医疗有限责任公司 | 包含半胱氨酸工程化抗体的轭合化合物 |
| HUE049622T2 (hu) | 2014-04-25 | 2020-09-28 | Rinat Neuroscience Corp | Magas drog-töltöttségû ellenanyag-drog konjugátumok |
| CA2949365A1 (en) * | 2014-05-16 | 2015-11-19 | Memorial Sloan Kettering Cancer Center | One-step labeling of antibodies to high specific activity with actinium-225 |
| WO2016016329A1 (en) | 2014-07-29 | 2016-02-04 | Vrije Universiteit Brussel | Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response |
| BE1021191B1 (fr) | 2014-08-29 | 2015-10-27 | Anmi S.A. | Kit pour radiomarquage. |
| GB201417067D0 (en) | 2014-09-26 | 2014-11-12 | South African Nuclear Energy | Radiopharmaceutical conjugate |
| DE102014115154A1 (de) | 2014-10-17 | 2016-04-21 | SCV-SpezialChemikalien-Vertrieb GmbH | Konjugierte Bisphosphonate für die Diagnostik und Therapie von Knochenerkrankungen |
| ES2822990T3 (es) | 2014-11-25 | 2021-05-05 | Bristol Myers Squibb Co | Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes |
| US20190015518A1 (en) * | 2016-01-04 | 2019-01-17 | University Of Kansas | Drug delivery compositions and methods |
| US10758634B2 (en) | 2016-03-18 | 2020-09-01 | Wake Forest University | Compounds, compositions and associated methods using zirconium-89 in immuno-positron emission tomography |
| CN108924931B (zh) * | 2017-03-24 | 2024-05-07 | 中兴通讯股份有限公司 | 一种无线资源配置方法、装置及用户设备、网络节点 |
| JP7191938B2 (ja) | 2017-05-05 | 2022-12-19 | センター・フォー・プローブ・デベロップメント・アンド・コマーシャライゼイション | Ｉｇｆ－１ｒモノクローナル抗体及びその使用 |
| US10093741B1 (en) * | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
| RU2019139432A (ru) | 2017-05-05 | 2021-06-07 | Сентр фор Проуб Девелопмент энд Коммерсиализэйшн | Фармакокинетическая оптимизация бифункциональных хелатов и их применение |
-
2018
- 2018-05-04 RU RU2019139432A patent/RU2019139432A/ru unknown
- 2018-05-04 IL IL270453A patent/IL270453B2/en unknown
- 2018-05-04 MA MA048861A patent/MA48861A/fr unknown
- 2018-05-04 EP EP18793830.3A patent/EP3619191A4/en active Pending
- 2018-05-04 JP JP2020511868A patent/JP7693317B2/ja active Active
- 2018-05-04 CN CN201880039130.2A patent/CN111263747B/zh active Active
- 2018-05-04 WO PCT/US2018/031228 patent/WO2018204869A1/en not_active Ceased
- 2018-05-04 KR KR1020197036026A patent/KR102612882B1/ko active Active
- 2018-05-04 EA EA201992595A patent/EA201992595A1/ru unknown
- 2018-05-04 CA CA3062553A patent/CA3062553C/en active Active
- 2018-05-04 CN CN202311319694.0A patent/CN117603148A/zh active Pending
- 2018-05-04 BR BR112019023246-0A patent/BR112019023246B1/pt active IP Right Grant
- 2018-05-04 AU AU2018261888A patent/AU2018261888B2/en active Active
- 2018-05-04 US US15/971,963 patent/US11191854B2/en active Active
-
2019
- 2019-11-05 CL CL2019003168A patent/CL2019003168A1/es unknown
- 2019-12-04 ZA ZA2019/08071A patent/ZA201908071B/en unknown
-
2021
- 2021-11-02 US US17/517,039 patent/US20220054664A1/en active Pending
-
2022
- 2022-08-24 AU AU2022221451A patent/AU2022221451A1/en not_active Abandoned
-
2023
- 2023-04-12 JP JP2023065085A patent/JP2023090748A/ja active Pending
-
2024
- 2024-10-29 AU AU2024227706A patent/AU2024227706A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018261888B2 (en) | 2022-06-30 |
| AU2018261888A1 (en) | 2019-11-28 |
| AU2024227706A1 (en) | 2024-11-21 |
| EA201992595A1 (ru) | 2020-04-21 |
| EP3619191A1 (en) | 2020-03-11 |
| JP2023090748A (ja) | 2023-06-29 |
| MA48861A (fr) | 2020-04-01 |
| IL270453A (enExample) | 2020-12-31 |
| IL270453B2 (en) | 2025-05-01 |
| BR112019023246A8 (pt) | 2021-02-23 |
| CA3062553C (en) | 2024-02-06 |
| BR112019023246B1 (pt) | 2023-11-14 |
| KR102612882B1 (ko) | 2023-12-11 |
| KR20200006087A (ko) | 2020-01-17 |
| IL270453B1 (en) | 2025-01-01 |
| CN111263747A (zh) | 2020-06-09 |
| BR112019023246A2 (pt) | 2020-05-19 |
| CN111263747B (zh) | 2023-10-27 |
| AU2022221451A1 (en) | 2022-09-22 |
| CA3062553A1 (en) | 2018-11-08 |
| NZ759832A (en) | 2025-05-30 |
| RU2019139432A3 (enExample) | 2021-06-16 |
| ZA201908071B (en) | 2023-04-26 |
| US20190030194A1 (en) | 2019-01-31 |
| JP2020518673A (ja) | 2020-06-25 |
| CL2019003168A1 (es) | 2020-08-28 |
| WO2018204869A1 (en) | 2018-11-08 |
| US20220054664A1 (en) | 2022-02-24 |
| JP7693317B2 (ja) | 2025-06-17 |
| US11191854B2 (en) | 2021-12-07 |
| EP3619191A4 (en) | 2020-12-16 |
| CN117603148A (zh) | 2024-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019139432A (ru) | Фармакокинетическая оптимизация бифункциональных хелатов и их применение | |
| JP2020518673A5 (enExample) | ||
| RU2019139434A (ru) | Моноклональные антитела против igf-1r и их применение | |
| JP7304588B2 (ja) | Ｐｓｍａを標的としたイメージング及び放射線治療のための金属／放射性金属標識ｐｓｍａ阻害剤 | |
| JP2020518674A5 (enExample) | ||
| JP2023090748A5 (enExample) | ||
| Chappell et al. | Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb | |
| Price et al. | Matching chelators to radiometals for radiopharmaceuticals | |
| AU2018207190B2 (en) | Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes | |
| JP2833766B2 (ja) | アミノポリカルボン酸およびその誘導体 | |
| TWI238722B (en) | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | |
| CA3071315A1 (en) | Dual mode radiotracer and -therapeutics | |
| JP2020520902A (ja) | 新規ｐｓｍａ結合剤及びその使用 | |
| WO2021075546A1 (ja) | 放射性金属標識抗体の製造方法 | |
| JP2023076712A (ja) | 放射標識生体分子およびその使用 | |
| JP2024523344A (ja) | 生物製剤を複数のキレーターと組み合わせるための方法及び材料 | |
| KR20240099208A (ko) | EGFRvIII-표적화 화합물 및 그의 용도 | |
| US20240350682A1 (en) | Steap2-targeted compounds and use thereof | |
| RU2025124374A (ru) | Способы лечения глиобластомы | |
| WO2025155818A1 (en) | Fibroblast activation protein-targeted radioligands with pharmacokinetic modulators | |
| TW202306983A (zh) | 抗ｃｄ２０抗體之放射性複合體，及放射性醫藥 | |
| EA050695B1 (ru) | Способ получения антитела, меченного радиоактивным металлом | |
| Price | Synthesis, Evaluation, and Application of New Ligands for Radiometal Based Radiopharmaceuticals | |
| CN116940557A (zh) | 化合物及放射性标记化合物 | |
| Burke | Positron emission tomography imaging agents with gallium-68: bifunctional chelators and multimodality |